Review and critical analysis of recent publications and meta-analyses on the use of 尾-blockers and other heart rate–slowing medicines in heart failure.
The reasons for the lack of effect of 尾-blockers in patients with heart failure are uncertain. There is a substantial body of evidence to suggest that patients with heart failure and atrial fibrillation who have less stringent ventricular rate control have a better outcome. The most plausible explanation for these findings, in our view, is that 尾-blockers exert similar benefits through similar mechanisms regardless of intrinsic heart rhythm but that the benefits of 尾-blockers are neutralized in patients with atrial fibrillation due to the induction of pauses that may impair cardiac function leading to worsening heart failure or cause arrhythmias resulting in death.
Smaller doses of 尾-blockers and other rate lowering agents to achieve a resting clinic heart rate in the range of 75-89beats/min might improve outcome. Preventing pauses by pacing or pulmonary vein ablation of atrial fibrillation are strategies that should be researched.